+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Defining the Future of the Stem Cell Industry - Interviews with Stem Cell Industry Executives

  • ID: 4319029
  • Report
  • July 2017
  • Region: Global
  • 166 Pages
  • BioInformant
1 of 3

Stem cell research has been in process for over five decades. Stem cells have a unique ability to divide and replicate repeatedly, as well as an “unspecialized” nature that allows them to differentiate into a wide variety of specialized cell types. In a developing embryo, stem cells can differentiate into all of the embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells.

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types. Several broad categories of stem cells exist, including:

  • Embryonic stem cells, derived from blastocysts
  • Perinatal stem cells, obtained during the period immediately before and after birth
  • Adult stem cells, found in adult tissues
  • Induced pluripotent stem cells (iPS cells), produced by genetically reprogramming adults cells
  • Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body

The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells as research tools, to utilization in cell therapies and integration into 3D printed tissues and organs. Additionally, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest to the pharmaceutical industry.

Rapid Technological Innovation

As a result of this technological innovation, the stem cell industry is undergoing rapid change. As of July 2017, a search for stem cells yields the following results:

  • 5,932 Clinical Trials - Search conducted via ClinicalTrials.gov, a global registry of clinical trials that contains approximately 3/4th of trials worldwide, using the terms “stem cell” or “stem cells”
  • 45,283 Patents - Search performed using the United State Patent and Trademark Office website, USPTO.gov, using the terms “stem cell” or “stem cells”
  • 296,399 Scientific Papers - Search performed on PubMed.gov, a global database of scientific publications maintained by the NIH, using the terms “stem cell” or “stem cells”
  • Google Trends identifies that stem cell terms are widely searched in countries worldwide, led by by Singapore, China, UK, USA, and Australia - Google Trends is a service of Google Inc. that identifies how frequently a particular search term is entered relative to total search volume worldwide

Undoubtedly, there is enormous interest surrounding the stem cell industry.  However, this rapid technological changes leaves all industry participants wondering, what will be the future directions for the stem cell industry over the next 5, 10, or 15 years?

Note: Product cover images may vary from those shown
2 of 3
  • Abstract
  • Interview with Kaz Hirao, CEO of CDI, a FUJIFILM Company – Industrial Scale Production of iPSCs and Differentiated Cells
  • Interview with Dr. Yael Margolin, CEO of Gamida Cell - Solving the Unmet Need inHematopoietic Stem Cell Transplantation (HSCT)
  • Interview with Dr. Frida Grynspan, VP of R&D for Stem Cell Medicine Ltd. - DevelopingGenetically Modified Muscle Progenitor Cells
  • Interview with Dr. Itzchak Angel, CEO of Accellta – Mass Production of Pluripotent Stem Cells 25
  • Interview with Eran Cohen, Intellectual Property (IP) Officer for Accellta – Small Company with the IP of a Big Company
  • Interview with Dr. Cynthia Bamdad, CEO of Minerva Biotechnologies - The Link Between Naïve Stem Cells and Cancer
  • Interview with Matthew Feshbach, Founder of Okyanos Cell Therapy (Part 1) - Adipose-Derived Stem Cell Therapies
  • Interview with Matthew Feshbach, Founder of Okyanos (Part 2) - Setting the Standard in Adipose-Derived Stem Cell Applications
  • Interview with Dr. Bruce Werber, COO of BPSR and CEO of Anu Life Sciences - Regenerative Applications of Placental Tissue Allografts
  • Interview with Dr. Ornella Parolini of IPLASS – Understanding Placental Stem Cell Applications
  • Interview with Pamela Levin of Tisch MS Research Center of NY – Beginning a Phase II Stem Cell Trial for MS
  • Interview with Dr. Saud Sadiq, Director of Tisch MS Research Center of NY - Stem Cells for Reversal of Multiple Sclerosis (MS)
  • Interview with James Alexis Mendez, CFO of CryoHoldco - Cord Blood Banking within Latin America
  • Interview with Kenneth Harris, Chief Advisor for CuraSense - Growth Rates & Trends within the Cord Blood Industry
  • Interview with Joseph Krieger of Boston Biolife - Educating Physicians about Regenerative Medicine
  • Interview with ORIG3N’s James Lovgren – Creating World’s Largest Blood Cell Repository for iPSC Production
  • Interview with Tony Veverka, Chief Group Executive of BioEden – How Dental Stem Cells Will Impact Our Future
  • Interview with João Andrade, CEO of WideCells Group – Unlocking the Future of Cord Blood Banking
  • Interview with Dr. Jon Rowley, Founder & CTO of RoosterBio - Radically Changing the Use of Stem Cells
  • Interview with Dr. Jon Rowley, Founder & CTO of RoosterBio - “Year of the Rooster”
  • Interview with Dr. Paul Wotton, Board Member of Cynata Therapeutics and Previous CEO of Ocata Therapeutics – Mass Production of Therapeutic Grade MSCs
  • Interview with Kyle Cetrulo, CEO of AuxoCell Laboratories – Future of Regenerative Medicine
  • Interview with Dr. Denver Lough, President and CEO of PolarityTE – Creating Functionally Polarized Tissue
  • Interview with Yaky Yanay, President and Co-CEO of Pluristem Therapeutics – Commercializing Placental Stem Cell Therapeutics
  • Interview with Dr. Priya Baraniak of RoosterBio - RM Industry’s First Xeno-free (XF) hMSC Cell Banks
  • Interview with Dr. Chris Centeno, CEO of Regenexx® – Orthopedic Applications of MSCs
  • Interview with Dr. Chris Centeno, CEO of Regenexx® - Visionary Behind Orthopedic Stem Cell Technology
  • Interview with Dr. Askenase of Yale University School of Medicine - MSC-Derived Exosomes for Spinal Cord Repair
  • Interview with Robin Smith, CEO of ORIG3N – Creating Patient-Specific iPSCs and a Living Database of Humanity
Note: Product cover images may vary from those shown
3 of 3

The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.

Input Sources

  • Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
  • Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
  • Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
  • Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
  • Product Launch Announcements (Trade Journals, Google News)
  • Industry Events (Google News, Google Alerts, Press Releases)
  • Company News (SEC Filings, Investor Publications, Historical Performance)
  • Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
  • Interviews with Stem Cell Industry Leaders

Research & Analysis Methodologies

The publisher employs the following techniques for deriving its market research:

  • Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
  • Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
  • Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
  • Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
  • Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
  • Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
  • Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).
 

Loading
LOADING...

Adroll
adroll